%20and%20Batch%20Production%20Records%20(BPR).png)
Why Medical Device & IVD PMS / Vigilance Reporting Is Fundamentally Different from Pharmaceutical PMS
Medical devices and in vitro diagnostics (IVDs) are regulated globally under frameworks such as the Medical Device Rules, 2017 (India), US FDA CFRs / QMSR, EU MDR (2017/745), and EU IVDR (2017/746). Across all these jurisdictions, manufacturers are legally obliged to establish Post-Market Surveillance (PMS) and Vigilance systems as integral components of their Quality Management System (QMS).
While the terminology may appear similar, medical device and IVD PMS/vigilance is fundamentally different from pharmaceutical pharmacovigilance (PV). The root of this difference lies in how these products work:
- Pharmaceuticals act through pharmacological, immunological, or metabolic mechanisms (PK/PD).
- Medical devices and IVDs are engineered products whose performance depends on design, materials, usability, software, and interaction with users—not on PK/PD.
This fundamental scientific distinction drives completely different regulatory philosophies for post-market safety monitoring, serious adverse event handling, and regulatory decision-making.
What Is PMS & Vigilance for Medical Devices and IVDs?
Post-Market Surveillance (PMS)
Post-Market Surveillance for medical devices and IVDs is a continuous, proactive, and systematic process designed to monitor a product’s real-world performance and safety throughout its entire lifecycle.
Key characteristics of device/IVD PMS include:
- Continuous collection and review of data after market placement
Use of multiple real-world data sources, including:Customer complaints
- Service and maintenance data
- Registries and real-world evidence (RWE)
- Scientific literature
- Feedback from users and healthcare professionals
- Evaluation of trends, failure modes, and performance drift
- Implementation of corrective and preventive actions (CAPA) when required
- What data will be collected
- How it will be analysed
How findings will feed back into:Risk management
- Clinical or performance evaluation
- Technical documentation
- Product improvement
Vigilance
Vigilance is the regulatory reporting arm of the PMS system and focuses on:
- Serious incidents
- Field Safety Corrective Actions (FSCAs)
- Trend reporting of non-serious incidents
Key points about vigilance in the device/IVD context:
- Vigilance is linked to PMS, but is a distinct regulatory activity
- It focuses on timely reporting to authorities, not just internal analysis
- Reports are typically submitted using standardized formats such as the Manufacturer Incident Report (MIR)
Why Medical Device & IVD PMS Is Fundamentally Different from Pharmaceutical Pharmacovigilance
The Scientific Foundation: PK/PD vs Engineered Performance
Pharmaceutical products exert their effect through pharmacokinetics (PK) and pharmacodynamics (PD). This means:
- Drug safety and efficacy must be fully characterised before approval
- Dose, metabolism, systemic exposure, and biological variability play a critical role
- A serious adverse drug reaction may indicate an inherent, non-correctable risk
As a result, in pharmaceuticals:
- Serious safety signals may lead to market withdrawal, suspension, or bans
- Products may remain unavailable until safety is conclusively re-established
In contrast, most medical devices and IVDs do not act via PK/PD mechanisms. They are engineered systems, where safety and performance depend on:
- Design and materials
- Manufacturing controls
- Software and algorithms
- Human factors and usability
- Instructions for use and training
This means that many post-market risks in devices are correctable, not intrinsic.
Medical Device & IVD PMS / Vigilance vs Pharmaceutical Pharmacovigilance
| Feature | Medical Device & IVD PMS / Vigilance | Pharmaceutical Pharmacovigilance |
|---|---|---|
| Primary Focus | Real-world performance, safety, and usability | Drug safety and adverse reactions |
| Mode of Action | Physical, mechanical, electrical, or software-based (no PK/PD) | Pharmacological / metabolic (PK/PD-driven) |
| System Structure | Integrated into the Quality Management System (QMS) | Stand-alone pharmacovigilance system |
| Data Sources | Complaints, RWE, registries, service data, user feedback | Spontaneous ADRs, clinical studies |
| Serious Events | Assessed against device-specific incident criteria | All serious suspected ADRs reported |
| Regulatory Outcome | CAPA, design change, labeling update, FSCA | Restriction, suspension, or ban |
| Lifecycle Approach | Continuous improvement expected | Limited post-approval modification |
Why This Difference Matters to Auditors & Regulators
During inspections and audits, regulators do not evaluate medical device and IVD PMS systems using pharmaceutical pharmacovigilance logic.
- PMS must demonstrate active performance monitoring, not passive event logging
- Vigilance reports must show root cause evaluation, not only timelines
- CAPA must be visibly linked to PMS trends and real-world evidence
- Design, labeling, or usability improvements are expected outcomes, not failures
Applying pharmaceutical pharmacovigilance expectations to device PMS is a common cause of nonconformities under MDR, IVDR, and global device regulations.
Medical Device & IVD PMS: Closed-Loop Lifecycle Model
Complaints, RWE, registries,
literature, service data
Performance drift,
failure modes
Serious incident?
FSCA required?
Design, process,
labeling, training
Risk management,
clinical/performance evaluation
This continuous improvement loop is a regulatory expectation for medical devices and IVDs and is fundamentally different from pharmaceutical pharmacovigilance models.
Frequently Asked Questions (FAQ)
Q1: Why are serious adverse events treated differently for devices and drugs?
Medical devices and IVDs are engineered products whose risks can often be mitigated through
design changes, CAPA, or usability improvements. Drugs act via PK/PD mechanisms, where serious
risks may be inherent and non-correctable.
Q2: Can a medical device remain on the market after a serious incident?
Yes. If root cause analysis identifies correctable factors and effective CAPA is implemented,
devices may remain on the market with improved safety controls.
Q3: Is PMS mandatory even if no complaints are received?
Yes. PMS requires proactive data collection and analysis. Absence of complaints does not
justify absence of surveillance activities.
Q4: Do IVDs follow the same PMS philosophy as medical devices?
Yes. IVD PMS focuses on diagnostic performance, clinical evidence, and real-world reliability,
rather than pharmacological safety.
Q5: When do PK/PD principles apply to medical devices?
PK/PD considerations apply to drug-device combination products, devices incorporating medicinal
substances, long-term implants with drug release, or products involving tissues or cells of
human origin.
Pharmaceutical pharmacovigilance asks “Is this drug fundamentally safe?”
Medical device PMS asks “How can this product be improved to remain safe and effective in real-world use?”
Regulatory Requirements for Device & IVD PMS and Vigilance
PMS System Mandate
Under MDR and IVDR, manufacturers must:
- Plan, establish, document, implement, maintain, and update a PMS system
- Ensure the system is proportionate to device risk class
- Actively generate and analyse post-market data
Mandatory PMS outputs include:
- PMS Reports (for lower-risk devices)
- Periodic Safety Update Reports (PSURs) (for higher-risk devices)
These reports summarise:
- Post-market findings
- Trend analysis
- CAPA taken or planned
- Benefit-risk conclusions
Vigilance Reporting
Manufacturers must report:
- Serious incidents
- Field Safety Corrective Actions (FSCAs)
- Statistically significant adverse trends
Critical Regulatory Expectation:
Authorities expect manufacturers to be proactive, not passive. Waiting for serious harm to occur before acting is considered non-compliant in device regulation.
Interactive PMS & Vigilance Decision Tool
Risk-based complaint evaluation with automatic CAPA and reporting logic for Medical Devices and IVDs.
Decision Record Details
Risk Class (Select Once)
Select product category:
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
